News | February 10, 2023
Lupin Q2 FY23 revenue up 3.9%; Profit down 71%
With the recent sales force expansion and new product launches, we expect to be back to above-market growth
With the recent sales force expansion and new product launches, we expect to be back to above-market growth
Revenue from operations during the quarter was up by 6.7 per cent to Rs 6,407.10 crore against Rs 6,002.2 in the same period last fiscal.
The company is in the process of appointing the new Chief Financial Officer shortly and in the interim, Komal Gupta will continue as CFO
Operating EBITDA grew by 82.7 % to Rs. 14.4 crore, EBITDA margin at 23.9%, and Profit After Tax (PAT) grew by 47.1% to Rs. 7.8 crore
Profit after Tax stood at Rs. 106 crore as compared to Rs. 84 crore registering growth of 26%
The company completed paracetamol capacity expansion by 1,800 MTPA and the company is now focusing on frugal manufacturing practices to reduce raw material cost and expand margins
Net sales for 9M FY23 up 9% to Rs. 4,246 crore and net profit for 9M FY23 at Rs. 189 crore
SEEDS is a mnemonic for Shun Tobacco, Eat Correctly, Exercise Regularly, Dump obesity and excess alcohol, and Stay vigilant about your family history aims at making more and more people aware about the tenets of cancer prevention
At the end of the inspection, the facility received two observations, one on written production process control procedure and the other on investigation procedure
A pharma industry veteran with over three decades of experience in domestic as well as international markets
Subscribe To Our Newsletter & Stay Updated
